Severine R. Vermeire
Expertise in
25
conditions

Severine R. Vermeire

Leuven, VLG, BE 
Expertise in
25
conditions
Leuven, VLG, BE 

Overview

Severine Vermeire practices in Leuven, Belgium. Ms. Vermeire is highly rated in 25 conditions, according to our data. Her top areas of expertise are Ulcerative Colitis, Hemorrhagic Proctocolitis, Colitis, Endoscopy, and Colonoscopy.

Her clinical research consists of co-authoring 821 peer reviewed articles and participating in 8 clinical trials. MediFind looks at clinical research from the past 15 years.

Gender

Female

Locations

Leuven, VLG, Belgium
Other Locations
Merelbeke, VLG 9820, Belgium

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

8 Clinical Trials

Drug Repurposing - Statins as Microbiota Modulating Agents in Ulcerative Colitis
Drug Repurposing - Statins as Microbiota Modulating Agents in Ulcerative Colitis
Enrollment Status: Terminated
Publish Date: November 25, 2025
Intervention Type: Drug
Study Phase: Phase 2/Phase 3
A Follow-up Phase II Open-label Study to Evaluate the Long-term Safety and Efficacy Profile of ABX464 Given at 25 mg Once Daily in Subjects With Moderate to Severe Active Ulcerative Colitis
A Follow-up Phase II Open-label Study to Evaluate the Long-term Safety and Efficacy Profile of ABX464 Given at 25 mg Once Daily in Subjects With Moderate to Severe Active Ulcerative Colitis
Enrollment Status: Active_not_recruiting
Publish Date: September 04, 2025
Intervention Type: Drug
Study Drug: ABX464
Study Phase: Phase 2
A Phase 3 Long-term Safety Extension Study of SHP647 in Subjects With Moderate to Severe Ulcerative Colitis or Crohn's Disease (AIDA)
A Phase 3 Long-term Safety Extension Study of SHP647 in Subjects With Moderate to Severe Ulcerative Colitis or Crohn's Disease (AIDA)
Enrollment Status: Completed
Publish Date: June 21, 2024
Intervention Type: Drug
Study Drug: Ontamalimab
Study Phase: Phase 3
Prospective Study to Assess the Efficacy of Switching to Infliximab in Moderately to Severely Active Chrohn's Disease Patients With Primary Non-response or Loss of Response to Adalimumab
Prospective Study to Assess the Efficacy of Switching to Infliximab in Moderately to Severely Active Chrohn's Disease Patients With Primary Non-response or Loss of Response to Adalimumab
Enrollment Status: Completed
Publish Date: January 05, 2023
Intervention Type: Drug
A Phase 3 Randomized, Double-blind, Placebo-controlled, Parallel-group Efficacy and Safety Study of SHP647 as Maintenance Therapy in Subjects With Moderate to Severe Ulcerative Colitis (FIGARO UC 303)
A Phase 3 Randomized, Double-blind, Placebo-controlled, Parallel-group Efficacy and Safety Study of SHP647 as Maintenance Therapy in Subjects With Moderate to Severe Ulcerative Colitis (FIGARO UC 303)
Enrollment Status: Completed
Publish Date: January 14, 2022
Intervention Type: Other, Drug
Study Phase: Phase 3
PhaRmacOkinetics and PHarmacodynamic BiomarkErs of Janus Kinase Inhibitor Therapy in PatIents With Ulcerative Colitis (PROPHETIC)
PhaRmacOkinetics and PHarmacodynamic BiomarkErs of Janus Kinase Inhibitor Therapy in PatIents With Ulcerative Colitis (PROPHETIC)
Enrollment Status: Terminated
Publish Date: January 04, 2022
Intervention Type: Drug
A Phase 3 Randomized, Double-blind, Placebo-controlled, Parallel-group Efficacy and Safety Study of SHP647 as Induction Therapy in Subjects With Moderate to Severe Ulcerative Colitis (FIGARO UC 302)
A Phase 3 Randomized, Double-blind, Placebo-controlled, Parallel-group Efficacy and Safety Study of SHP647 as Induction Therapy in Subjects With Moderate to Severe Ulcerative Colitis (FIGARO UC 302)
Enrollment Status: Terminated
Publish Date: April 26, 2021
Intervention Type: Drug
Study Phase: Phase 3
An Open Label Interventional Phase 4 Study to Evaluate Efficacy, Safety and Mucosal Healing of Early Versus Late Use of Vedolizumab in Ulcerative Colitis: the LOVE-UC Study (LOw Countries VEdolizumab in UC Study)
An Open Label Interventional Phase 4 Study to Evaluate Efficacy, Safety and Mucosal Healing of Early Versus Late Use of Vedolizumab in Ulcerative Colitis: the LOVE-UC Study (LOw Countries VEdolizumab in UC Study)
Enrollment Status: Completed
Publish Date: October 08, 2020
Intervention Type: Drug
Study Phase: Phase 4
View 7 Less Clinical Trials

818 Total Publications

Personalized infliximab rescue therapy to maximize colectomy-free survival in patients with acute severe ulcerative colitis.
Personalized infliximab rescue therapy to maximize colectomy-free survival in patients with acute severe ulcerative colitis.
Journal: Journal of Crohn's & colitis
Published: March 24, 2026

Frequently Asked Questions about Severine R. Vermeire

Is Severine R. Vermeire a top-rated expert for Ulcerative Colitis?

MediFind is an objective health platform that identifies experts based on real-world data. Severine R. Vermeire is classified as an Elite expert for Ulcerative Colitis, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Severine R. Vermeire participate in research or clinical trials?

Yes. Severine R. Vermeire has published 818 articles and abstracts on conditions like Ulcerative Colitis. You can view a list of Severine R. Vermeire's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Ms. Vermeire's expertise for a condition
ConditionClose
View All 9 Elite Conditions
View All 11 Advanced Conditions
View All 38 Experienced Conditions
Want to save this expert for later?
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile